Author:
Horsmans Yves,Hu Ke,Ruffin Matthieu,Wang Ying,Song Dongweon,Bouillaud Emmanuel,Wang Yanfeng,Mazur Dago,Botha Frans-Peter,Heuman Douglas M.
Subject
Pharmacology (medical),Pharmacology
Reference15 articles.
1. Pasireotide (SOM230): development, mechanism of action and potential applications;Schmid;Mol Cell Endocrinol,2008
2. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial;Petersenn;J Clin Endocrinol Metab,2010
3. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR;Kvols;J Clin Oncol,2007
4. Efficacy, safety and pharmacokinetic results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR;Kvols;Neuroendocrinology,2010
5. Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial;Boscaro;J Clin Endocrinol Metab,2009
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献